Mercedes-backed ProLogium starts 381 Wh/kg solid-state production as carmakers watch from sidelines

ProLogium Technology has started mass production of its 381 Wh/kg solid-state battery cell, meeting China's GB/T 43568-2026 standard. The company, backed by Mercedes-Benz, aims to scale production but faces cost and volume challenges. Its current capacity is 0.5 GWh, with plans to expand. ProLogium's technology has been tested and certified, but its commercial viability for EVs remains uncertain.

Original reporting
Published Sep 6, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 6, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mercedes-backed ProLogium starts 381 Wh/kg solid-state production as carmakers watch from sidelines — source image
Decision brief

The 30-second read

Low
01

Why it matters

The announcement marks the first commercial rollout of a high‑energy solid‑state cell, but the small 0.5 GWh initial capacity limits near‑term market impact.

02

Market read

While the technology breakthrough is notable, the limited production scale and lack of cost disclosure constrain immediate trading relevance for listed equities.

03

What to watch

Regulatory standard GB/T 43568 may become a de‑facto benchmark, giving ProLogium early mover advantage if adopted internationally.

Relevance 5/10Novelty 6/10Timing: mass production announced Sep 2, reported Sep 6

Background

ProLogium Technology, a Taiwanese battery developer, announced the start of mass production for its Generation 3.5 solid‑state lithium‑ceramic cell with 381 Wh/kg energy density.

Market effects

demonstrates progress in solid‑state battery tech, may spur further R&D investment in EV battery sector.

boosts Taiwan's battery manufacturing profile and could influence European EV supply chains with the planned French plant.

adds a new competitor to the global solid‑state race, but limited immediate impact on major listed battery makers.

Counterpoint

Without disclosed cost data, the high energy density may not translate into commercial advantage; larger incumbents could maintain lead.

Key entities

  • ProLogium Technology

    Taiwanese solid‑state battery developer launching mass production.

  • Mercedes‑Benz

    Automotive partner in a technology cooperation agreement with ProLogium.

Related articles

Low

ProLogium Technology Co., Ltd.: Mercedes-Benz and ProLogium have entered into a joint testing agreement, including a preliminary technology evaluation of ProLogium's latest Gen4 Superfluidized All Inorganic Solid State Battery Cell Technology

Mercedes-Benz and ProLogium have signed a joint testing agreement for ProLogium's Gen4 solid-state battery cells, building on a decade-long partnership. The agreement grants Mercedes-Benz priority access to test the technology, which offers high energy density, safety, and performance. ProLogium plans to go public on NASDAQ in 4Q2026 under the ticker PRLG.

$PRLGMed

ProLogium Ships First Solid-State Cells as Dunkirk Factory Rises

ProLogium Technology has started mass production of its lithium-ceramic battery cells in Taiwan, achieving 381 watt-hours per kilogram. The company is building a €5.2 billion gigafactory in Dunkirk, France, with production expected to begin in 2028. ProLogium aims to list shares on Nasdaq under ticker PRLG via a SPAC merger valued at $3.8 billion. The company has partnerships with Mercedes-Benz and Rimac, and its technology promises higher energy density and improved safety for electric vehicles

$TDACMedAI 8/10

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

$LLYMed

Retatrutide Cut Sleep Apnea Breathing Events Up to 60.6% in Lilly Trial, but the Weekly Shot Remains Unapproved

Eli Lilly reported that retatrutide, an experimental weekly injection, reduced breathing interruptions in sleep apnea patients by up to 60.6% in an 80-week trial. The drug also showed a 48.1% reduction in a separate trial involving Type 2 diabetes patients. Lilly plans to seek FDA approval in early 2027, but the drug is not yet approved for any use. The results were presented at ObesityWeek 2026, with full peer-reviewed data not yet published.

$LHXMed

Airlines cancel thousands more flights after FAA ground stop

A router installed by L3Harris caused a nationwide US flight shutdown on November 13, leading to 4,500 cancellations and 4,400 delays on November 14. Transportation Secretary Sean Duffy noted the disruption was not a cyberattack but due to potential user or installer error. Major airlines canceled about 20% of flights, with JetBlue canceling 40%. The FAA is investigating and expects operations to normalize by late November 15. Duffy requested $50 billion to upgrade air traffic control systems.